19: Introduction to Antinociceptive Drugs

CHAPTER 19 Introduction to Antinociceptive Drugs

Pain has always been a barrier to dentistry, serving as a continuing motivation for the use of drugs to prevent, block, or attenuate pain in the perioperative period. Despite the efficacy of local anesthesia, many procedures can result in substantial postoperative discomfort and edema, limiting mouth opening for several days. Poorly controlled pain in the perioperative period also contributes to anxiety about future dental therapy, leading to postponed or canceled appointments.2,10,16 Effective control of orofacial pain facilitates the delivery of care, reduces anxiety about dentistry, and may even improve dental health by promoting preventive and routine dentistry as an alternative to general neglect with episodic care for acute problems. Emerging basic and clinical studies have shown that the use of antinociceptive drugs to attenuate perioperative pain can prevent the development of hyperalgesia manifesting as increased pain hours to days after a procedure. The availability of safe, effective antinociceptive drugs now permits effective prevention and management of perioperative pain for the mutual benefit of the patient and the dental practitioner.

The multiplicity of pain mechanisms and the difficulty of separating nociceptive processing from physiologic pain perception represent significant barriers to improving pain therapy. In addition to the molecular events associated with tissue injury, inflammation, development of sensitization, and activation of ascending and descending pathways, it is now recognized that gender and genetic factors also contribute to individual variation in pain perception, processing, and evaluation of nociceptive input. Because of this mechanistic complexity, use of analgesic drugs in fixed doses that have been validated in a relatively homogeneous patient sample may not result in effective therapy when used in a patient population with wide genetic diversity in pain processing and drug metabolism. Although individual variation in the human pain experience is traditionally explained by various factors such as cultural or psychological influences, more recent studies in animal and human pain models show phenotypic differences in pain sensitivity that may result from genetic factors.6,22,26,38,44 This genetic variation among patients, along with other sources of variation, provides a physiologic rationale for individualizing pain treatment.

The management of chronic pain has a long history of therapeutic misadventures, including the misuse of drugs for symptomatic relief of chronic orofacial pain. There is still no generally accepted agreement about the cause of chronic orofacial pain; its natural history; the need for aggressive treatment; and the effectiveness, safety, and indications for most clinical practices. Differences of opinion on these issues are often fostered by a lack of appreciation of the difference between clinical observations, which may form the basis for therapeutic innovation, and the need to verify the efficacy and safety of treatments in studies that control for factors that can mimic clinical success. Drug classes for the treatment of pain associated with temporomandibular joint (TMJ) disorders range from short-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants for pain of presumed muscular origin to long-term administration of antidepressants and anticonvulsants for less well-characterized pain (see Chapter 23). The management of pain associated with TMJ disorders rests on the same principles that apply to the use of all drugs: demonstrated efficacy for the indication, an acceptable incidence of adverse reactions for the condition being treated, and safety when used in numerous patients for prolonged periods.

Growing numbers of elderly people in the population increase the prevalence of age-related painful conditions, such as osteoarthritis and various neuropathies. Improvements in the management of cancer increase life expectancy but are accompanied by an increase in the cumulative incidence of cancer-related pain and painful conditions associated with cancer treatment (e.g., chemotherapy, radiotherapy, surgery). In these patients with a complicated history, currently available analgesic modalities are often not helpful or effective. Despite astonishing advances in understanding of the neurobiology of pain, pain continues to produce severe distress, dominating and disrupting the lives of many patients from lack of adequate pain relief or the consequences of its treatment.

PATHWAYS OF OROFACIAL PAIN

Pain Transduction and Transmission in the Periphery

Noxious stimuli, which can produce tissue damage, are detected by the terminal endings of two major classes of nociceptive (pain-detecting) afferent nerve fibers (Figure 19-1). These nociceptors are distributed throughout the skin, oral mucosa, and tooth pulp. Aδ fibers are fast-conducting, lightly myelinated neurons responding primarily to noxious mechanical stimuli. Aδ fibers are thought to mediate the initial sensation of pain, which has a sharp perceptual quality. The second group of nociceptive fibers comprises C fibers, which are slowly conducting unmyelinated neurons that respond to thermal, mechanical, and chemical stimuli. C fibers likely mediate secondary pain, which occurs after the initial sharp, pricking pain and is generally described as having a dull, aching, or burning perceptual quality. There are approximately three to five times more C fibers than Aδ fibers.29 Other classes of cutaneous fibers have been described but are not as well characterized.

The detection of noxious stimuli in the orofacial region and the encoding of pain are conveyed primarily by nerves of the trigeminal system. The trigeminal nerve, or fifth cranial nerve, is the largest of the cranial nerves; its three branches (ophthalmic, maxillary, and mandibular branches) innervate most of the face and anterior scalp. The trigeminal nerve also innervates the mucous membranes and gingivae of the mouth; the teeth and jaws; the anterior two thirds of the tongue; the nasopharynx, nasal cavities, and sinuses; and a portion of the meninges. The facial (seventh cranial) nerve encodes pain from the skin of the mastoid region and the external auditory meatus; most of the sensory function of this nerve is involved in taste sensation. The glossopharyngeal (ninth cranial) nerve innervates the back of the tongue, tonsillar region, tympanic cavity, and antrum and oronasal portions of the pharynx. The vagus (tenth cranial) nerve innervates the larynx and parts of the pharynx, ear, and external auditory meatus. These cranial nerves provide the peripheral innervation necessary for the detection of orofacial and dental pain.19

Pain Modulation in the Brainstem

The Aδ and C fibers from the orofacial region transmit nociceptive signals primarily by the branches of the trigeminal nerve to the trigeminal nucleus caudalis; noxious information from additional regions is conveyed by other cranial nerves. Most clinical and laboratory data indicate that the nucleus caudalis is the principal brainstem relay site for trigeminal nociceptive information.36 The nucleus caudalis is located in the medulla; its laminated structure, types of cells, and function in processing pain signals are similar to the area on the dorsal aspect of the spinal cord termed the dorsal horn.

As previously stated, the small-diameter afferents carrying nociceptive information from the various craniofacial tissues predominantly terminate in laminae I, II, and V of the nucleus caudalis. By contrast, primary afferent A fibers conducting low-threshold mechanosensitive (tactile) information terminate primarily in the most rostral components of the trigeminal brainstem complex and in laminae III to VI of the nucleus caudalis. More recent studies have also revealed increases in immunocytochemical markers of neuronal activity in caudalis neurons after noxious stimulation of craniofacial tissues.36 Additionally, numerous studies using microelectrode recording have shown that many neurons in the nucleus caudalis are activated by cutaneous nociceptive input from the craniofacial region. For these reasons, the nucleus caudalis has been termed the medullary dorsal horn.37

The medullary and spinal dorsal horns contain four major components related to the processing of noxious stimuli: central terminals of afferent fibers, local circuit neurons, projection neurons, and descending neurons. The first component, primary nociceptive afferents (Aδ and C fibers), enter the medullary dorsal horn by way of the trigeminal tract. Nerves that enter the spinal dorsal horn traverse the lateral aspect of the tract of Lissauer. For medullary and spinal dorsal horns, Aδ and C fibers terminate mainly in laminae I, IIa, and V. The primary nociceptive afferents transmit information by the synaptic release of neuropeptides (e.g., substance P, calcitonin gene–related peptide [CGRP]) and amino acids (e.g., glutamate).

The second component of the dorsal horn—the local circuit neurons—consists of two major subtypes, the islet cells and stalked cells. Islet cells are found throughout lamina II and are thought to be inhibitory interneurons possibly using γ-aminobutyric acid (GABA) or enkephalin as neurotransmitters. Stalked cells are found primarily at the junction between laminae I and II and have been proposed to be excitatory interneurons conveying nociceptive output from primary afferents to projection neurons located in lamina I. The local circuit neurons play a crucial role in conveying and modulating nociceptive signals from the primary afferents to the projection neurons.

Projection neurons constitute the third component of the dorsal horn. Their function, and that of the descending neurons, is described later. Projection neurons and local circuit neurons can be divided into two major classes: wide dynamic range and nociceptive-specific neurons. The wide dynamic range neurons are activated by weak mechanical stimuli but respond maximally to intense and potentially tissue-damaging stimuli. In contrast, nociceptive-specific neurons respond only to intense noxious forms of mechanical, thermal, or chemical stimuli.

PERIPHERAL MECHANISMS OF PAIN AND ANALGESIC DRUG ACTIONS

Activation of Nociceptors

Most noxious stimuli are transduced into electrical activity at the peripheral terminals of Aδ and C fibers by specific receptors or ion channels sensitive to heat, mechanical stimuli, protons, or cold. Ligand-gated channels expressed on nociceptive neurons include excitatory amino acid receptors, GABA receptors, nicotinic acetylcholine receptors, serotonergic (tryptaminergic or 5-hydroxytryptamine) receptors, and adenosine triphosphate P2X receptors. These receptors permit primary nociceptive neurons to respond to a wide range of mediators.28

Among the many channel types that modulate the passage of charged ions across cell membranes, Ca++ channels are particularly important in cellular homeostasis and activity, and the surface of each cell holds thousands of these channels that precisely control the timing and entry of Ca++. Small conformational changes cause these channels to open, allowing more than 10 million ions per second to flow through each channel. The opening of Ca++ channels is the crucial link between cell depolarization and Ca++ entry, which can result in local intracellular Ca++ concentrations up to 100 µmol/L. The subsequent binding of Ca++ to intracellular molecules can lead to many significant responses, including triggering of neurotransmitter release, the activation of second messenger systems, and Ca++ spikes (action potentials in which the depolarizing current is carried predominantly by Ca++).28

Transient receptor potential (TRP) channels are the vanguard of sensory systems, responding to temperature, touch, pain, osmolarity, and other stimuli. TRPV1, also known as the vanilloid receptor 1, is a Ca++-permeable channel that is opened by heat (>43° C) and decreased pH. TRPV1 contributes to acute thermal nociception and hyperalgesia after tissue injury. TRPV2, which is 50% identical to TRPV1 in primary structure, may mediate high-threshold (>52° C) noxious heat sensation, perhaps through lightly myelinated Aδ nociceptors. The ankyrin-like protein with transmembrane domains 1 channel is a Ca++-permeable, nonselective channel distinguished by approximately 14 amino-terminal ankyrin repeats. It is activated by noxious cold temperature (<15° C) but bears little similarity to the menthol-sensitive TRPV8 channel. It is found in a subset of nociceptive sensory dorsal root ganglion neurons in the company of capsaicin-sensitive TRPV1 channels.4

Activation of nociceptors is not the only way to trigger pain. After peripheral tissue injury or damage to the nervous system, low-threshold sensory fibers, which normally produce only innocuous sensations such as light touch, can begin to produce pain—a substantial change in the normal functional specificity of the sensory system. Although this pain no longer represents the presence of a damaging external stimulus, to the individual it feels as if the pain arises in the periphery from a noxious stimulus. With inflammation, components of the “inflammatory soup” such as bradykinin or prostaglandins bind to G protein–coupled receptors and induce activation of protein kinases A and C in nociceptor peripheral terminals, which phosphorylate ion channels and receptors. As a result, the threshold for activation of transducer receptors such as TRPV1 is reduced.

One of the best-established pronociceptive substances derived from nerve endings is substance P. Substance P causes vasodilation and extravasation of plasma proteins from capillaries, which contribute to the edema associated with inflammation and to the generation of bradykinin from kininogen. Because the neurokinin-1 receptor is the major receptor for substance P, neurogenic inflammation is markedly attenuated by receptor antagonists specific for this receptor. Another putative mediator of neurogenic inflammation is CGRP, which produces vascular leakage and vasodilation leading to inflammation and tenderness. Immune cells may be involved in inflammatory pain, cancer pain, and pain after nerve injury. They are activated in the periphery and within the central nervous system (CNS) in response to tissue damage, inflammation, or mechanical nerve lesions. The immune reaction may increase nociception through the release of cytokines, but granulocytes and monocytes can also promote analgesia by secreting β-endorphin and enkephalin.

Jan 5, 2015 | Posted by in General Dentistry | Comments Off on 19: Introduction to Antinociceptive Drugs
Premium Wordpress Themes by UFO Themes